3060 Pegasus Park Drive
Building 6
Dallas, TX 75247
United States
310 618 6994
https://www.fortebiorx.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 11
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Paul A. Wagner Ph.D. | CEO, President & Chairman | 960.23k | N/D | 1970 |
Mr. Antony A. Riley CPA | Chief Financial Officer | 568.48k | N/D | 1967 |
Dr. Barbara K. Finck M.D. | Chief Medical Clinician & Director | 45k | N/D | 1947 |
Mr. Christopher Roenfeldt | Chief Operating Officer | N/D | N/D | N/D |
Mr. Steven Ruhl | Chief Technical Officer | N/D | N/D | 1957 |
Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
La calificación ISS Governance QuickScore de Forte Biosciences, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.